Indication

Carcinoid syndrome diarrhea

Carcinoid syndrome diarrhea is a chronic, secretory gastrointestinal complication that occurs in patients with advanced, well-differentiated neuroendocrine tumors, most often originating in the midgut and metastatic to the liver. Read more about Carcinoid syndrome diarrhea

3 drugs 3 manufacturers

Advertisement

Drugs that treat it

Common Carcinoid syndrome diarrhea therapies.

Showing 1–3 of 3 drugs

Filter & compare in the drug finder →Opens the drug finder with Carcinoid syndrome diarrhea preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Carcinoid syndrome diarrhea.

Carcinoid syndrome diarrhea is a chronic, secretory gastrointestinal complication that occurs in patients with advanced, well-differentiated neuroendocrine tumors, most often originating in the midgut and metastatic to the liver.

It develops when tumor cells release excess humoral mediators—predominantly serotonin (5-hydroxytryptamine), along with tachykinins and prostaglandins—directly into the systemic circulation, bypassing hepatic first-pass metabolism.

Within the digestive tract, this hypersecretion stimulates intestinal motility, accelerates gut transit, and promotes colonic electrolyte and water secretion while impairing absorption.

Clinically, it is characterized by frequent, debilitating, watery bowel movements often accompanied by abdominal cramping, tenesmus, and malabsorption, occurring either alongside or independently of other classic carcinoid manifestations like cutaneous flushing.

Personalize your experience

Follow Carcinoid syndrome diarrhea and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it